These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 28744099)

  • 1. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
    Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
    Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
    J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
    Hall J; Gillen M; Yang X; Shen Z
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):179-187. PubMed ID: 29688628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
    Shen Z; Rowlings C; Kerr B; Hingorani V; Manhard K; Quart B; Yeh LT; Storgard C
    Drug Des Devel Ther; 2015; 9():3423-34. PubMed ID: 26170627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
    Smith WB; Hall J; Berg JK; Kazimir M; Yamamoto A; Walker S; Lee CA; Shen Z; Wilson DM; Zhou D; Gillen M; Marbury TC
    Clin Drug Investig; 2018 Aug; 38(8):703-713. PubMed ID: 29949102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
    Lee CA; Yang C; Shah V; Shen Z; Wilson DM; Ostertag TM; Girardet JL; Hall J; Gillen M
    Drug Metab Dispos; 2018 May; 46(5):532-541. PubMed ID: 29490903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
    Fleischmann R; Winkle P; Miner JN; Yan X; Hicks L; Valdez S; Hall J; Liu S; Shen Z; Gillen M; Hernandez-Illas M
    RMD Open; 2018; 4(1):e000584. PubMed ID: 29531784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.
    Fleischmann R; Winkle P; Hall J; Valdez S; Liu S; Yan X; Hicks L; Lee C; Miner JN; Gillen M; Hernandez-Illas M
    RMD Open; 2018; 4(1):e000647. PubMed ID: 29657831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants.
    Johansson S; Han D; Hunt T; Björck K; Florica D; Gillen M; Hall J; Erlandsson F
    Pharmacol Res Perspect; 2022 Jun; 10(3):e00929. PubMed ID: 35593744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.